Disease Focus
We are committed to developing next-generation treatments for individuals suffering from corneal neuropathic pain and rare corneal disease. Our aim is to create innovative therapies that not only alleviate ocular pain but also address the limitations of current treatments by offering a novel approach to controlling inflammation.
Innovative Approach for Inflammatory Eye Diseases
Neuropathic Corneal Pain (NCP)
- NCP, a severe, chronic, and debilitating disease for which there are no approved commercial treatments currently available.
- Current treatments are limited to short term NSAIDs, steroids, and opioids in severe cases. Side effects and the risk of addiction to opioids is a serious concern
- Often underdiagnosed, as the symptoms can overlap with other eye conditions, and treatment can be difficult to manage effectively.
- ChemR23 receptor on leukocytes targeted by urcosimod is also expressed on neurons and glial cells in the dorsal root ganglion and spinal cord
- Topical administration of urcosimod was effective in suppressing corneal pain in a ciliary nerve ligation mouse model of NCP similar to that of gabapentin, a commonly used oral drug for neuropathic pain, given by intraperitoneal injection.
- The pain-relieving potential of urcosimod is very important because a considerable number of dry eye patients with chronic inflammation also suffer from ocular pain.
Rare Corneal Disease
- Coming Soon!